Related Experiment Video
Updated: Nov 24, 2025

Histological Quantification of Chronic Myocardial Infarct in Rats
Published on: December 11, 2016
Association Between Myocardial Scar Burden and Left Ventricular Ejection Fraction in Ischemic Cardiomyopathy
Fatma Aboul Enein1,2, Sarah Allaaboun3, Samiha Khayyat3
1Cardiology, Alexandria University Faculty of Medicine, Alexandria, EGY.
Insights
Myocardial scar burden and left anterior descending artery viability predict ejection fraction improvement after cardiac events. These factors are key for recovery, even with standard medications.
Area of Science:
- Cardiology
- Medical Imaging
- Heart Failure Research
Background:
- Assessing the relationship between scar burden and left ventricular ejection fraction (LVEF) is crucial for understanding heart function recovery.
- Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging is a standard method for quantifying myocardial scar.
- Patient LVEF is often categorized as non-severe or severely depressed, impacting prognosis.
Purpose of the Study:
- To evaluate the correlation between the extent and severity of myocardial scar and follow-up LVEF.
- To identify predictors of LVEF improvement in patients with reduced ejection fraction.
Main Methods:
- Cardiovascular magnetic resonance imaging with LGE was used to assess scar burden (scar score).
- Baseline and follow-up ejection fractions (EF) were recorded for 178 patients.
- Statistical analyses included linear and binary regression to identify predictive factors.
Main Results:
- Patients with severe baseline LVEF had a significantly higher mean scar percentage.
- Aldosterone antagonists and total scar score were significant predictors of follow-up EF.
- Left anterior descending artery (LAD) territory viability and baseline EF predicted EF change in patients with LVEF ≤ 35%.
Conclusions:
- Myocardial scar extent and LAD territory viability are independent predictors of EF improvement.
- These parameters remain significant even after adjusting for demographics, baseline EF, and standard medications.
- Understanding scar burden and viability aids in predicting cardiac recovery and guiding treatment strategies.
Abstract:
Background This study was conducted to assess the relationship between scar burden (extent and severity) and the follow-up left ventricular ejection fraction (LVEF). Methods Patients were referred for viability assessment with late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging. To measure the transmural extent of LGE in each segment (scar score), we used a five-point scale system. Baseline ejection fraction (EF) and at follow-up were recorded. LVEF classified as non-severe and severely depressed. Results The study included 178 patients (males: 88.8%; mean age: 57.1±10.02 years; mean baseline LVEF: 28.61±10.39). In patients with severe baseline LVEF, the mean scar percentage was higher than that in patients who had non-severe LVEF (38.8±19.41 vs. 24.61±21.21; p˂0.001). On linear regression analysis, aldosterone antagonist and total scar score significantly predicted follow-up ejection fraction (EF) (B=-7.083, p˂0.001 and B=-3.038, p=0.038, respectively). Left anterior descending artery (LAD) territory viability and baseline EF significantly predicted change in EF in patients with LVEF ≤ 35% (B=5.389, p=0.009 and B=-0.581, p˂0.001, respectively). On binary regression analysis for the prediction of at least 5% improvement in EF in patients with baseline EF ≤ 35%, baseline EF and LAD viability were significant (B=-0.15, p=0.014 and B=1.042 and p=0.054, respectively). Conclusions The extent of myocardial scar and viability of LAD territory are identified as the important and independent parameters for the predictions of improvement in EF even after adjustment for demographics and baseline EF and following the standards of care medication.
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis I: Introduction
Pathophysiology of Heart Failure
Cardiomyopathy II: Dilated Cardiomyopathy

